A mitochondrial-targeted nanomedicine based on hollow mesoporous silica nanoparticles for enhanced colorectal cancer therapy

IF 4.7 3区材料科学 Q2 CHEMISTRY, PHYSICAL

Colloid and Interface Science Communications Pub Date : 2025-03-25 DOI:10.1016/j.colcom.2025.100833

Jin Liu , Tianle Liu , Chi Zhang , Ziyou Wang , Xinyi Zhang , Chuanchuan Hao , Dan Wang , Guohui Cheng

{"title":"A mitochondrial-targeted nanomedicine based on hollow mesoporous silica nanoparticles for enhanced colorectal cancer therapy","authors":"Jin Liu , Tianle Liu , Chi Zhang , Ziyou Wang , Xinyi Zhang , Chuanchuan Hao , Dan Wang , Guohui Cheng","doi":"10.1016/j.colcom.2025.100833","DOIUrl":null,"url":null,"abstract":"<div><div>By focusing on mitochondria as a therapeutic target, strategies can be devised to deplete ATP levels, thereby potentially circumventing the emergence of MDR. In this study, we developed a surface-modified hyaluronic acid (HA), mitochondrial targeted hollow mesoporous silicon nanomedicine (PB@HMSN-HA) co-loaded with berberine (BBR) and paclitaxel (PTX) for enhanced colorectal cancer therapy. The modified HA can selectively bind to tumor cells that overexpress the CD44 receptor, leading to the accumulation of PB@HMSN-HA at the tumor site and improving tumor targeting efficiency. After cellular internalization, the liberated positively charged BBR, which is specifically targeted to mitochondria, induces a reduction in ATP levels. Depletion of ATP subsequently results in a reduction of drug efflux, thereby amplifying the antitumor efficacy of PTX. Therefore, this combination therapy strategy targeting mitochondria serves as an important reference for clinical oncological chemotherapy.</div></div>","PeriodicalId":10483,"journal":{"name":"Colloid and Interface Science Communications","volume":"66 ","pages":"Article 100833"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colloid and Interface Science Communications","FirstCategoryId":"88","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2215038225000172","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

Abstract

By focusing on mitochondria as a therapeutic target, strategies can be devised to deplete ATP levels, thereby potentially circumventing the emergence of MDR. In this study, we developed a surface-modified hyaluronic acid (HA), mitochondrial targeted hollow mesoporous silicon nanomedicine (PB@HMSN-HA) co-loaded with berberine (BBR) and paclitaxel (PTX) for enhanced colorectal cancer therapy. The modified HA can selectively bind to tumor cells that overexpress the CD44 receptor, leading to the accumulation of PB@HMSN-HA at the tumor site and improving tumor targeting efficiency. After cellular internalization, the liberated positively charged BBR, which is specifically targeted to mitochondria, induces a reduction in ATP levels. Depletion of ATP subsequently results in a reduction of drug efflux, thereby amplifying the antitumor efficacy of PTX. Therefore, this combination therapy strategy targeting mitochondria serves as an important reference for clinical oncological chemotherapy.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Colloid and Interface Science Communications Materials Science-Materials Chemistry

CiteScore

9.40

自引率

6.70%

发文量

125

审稿时长

43 days

期刊介绍： Colloid and Interface Science Communications provides a forum for the highest visibility and rapid publication of short initial reports on new fundamental concepts, research findings, and topical applications at the forefront of the increasingly interdisciplinary area of colloid and interface science.